Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Characteristics of patients receiving mepolizumab in real-world practice –REALITI-A study

Next Previous
Trial Profile

Characteristics of patients receiving mepolizumab in real-world practice –REALITI-A study

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms REALITI-A
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 22 May 2024 Results assessing prior omalizumab use and baseline blood eosinophil count alone, and in combination with total serum IgE, on maintenance OCS reduction outcomes in patients with severe asthma treated with mepolizumab were presented at the 120th International Conference of the American Thoracic Society.
  • 26 Feb 2024 Results of Patient and Physician Perspectives on Mepolizumab Treatment in Severe Asthma, presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  • 13 Sep 2023 Results of post hoc analysis by exacerbation history, presented at the 33rd Annual Congress of the European Respiratory Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top